^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Anniko (penpulimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Akeso Biopharma Press Release
    Title:

    China NMPA Approved Penpulimab for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC

    Published date:
    01/15/2023
    Excerpt:
    Akeso, Inc...announced that the anti PD-1 monoclonal antibody drug penpulimab, co-developed by the Company with Sino Biopharmaceutical...combined with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC) has been granted marketing approval by the National Medical Products Administration (NMPA) of China.
    Secondary therapy:
    Chemotherapy